Eli Lilly and Company has announced positive data from its Phase II study of cixutumumab in five subtypes of sarcoma, a cancer related to connective tissues.

The Phase II trial included 113 patients with advanced or metastatic soft tissue sarcoma and in the Ewing family of tumours, and demonstrated that 57% of patients taking cixutumumab experienced stable disease.

The study was evaluated in five tiers and the overall response was reported as one partial response in the Ewing sarcoma tier, stable disease of 41% in leiomyosarcoma, 35% in synovial sarcoma, 28% in Ewing family of tumours and 24% in rhabdomyosarcoma.

The treatment-related adverse affects include hyperglycaemia, asthenia, pain and thrombocytopenia.

Cixutumumab is a monoclonal antibody that targets the insulin-like growth factor-1 receptor, which plays a major role in cancer cell proliferation, survival and resistance to therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.